STOCK TITAN

ETF Series Solutions Trust Range Cancer Therapeutics ETF - CNCR STOCK NEWS

Welcome to our dedicated page for ETF Series Solutions Trust Range Cancer Therapeutics ETF news (Ticker: CNCR), a resource for investors and traders seeking the latest updates and insights on ETF Series Solutions Trust Range Cancer Therapeutics ETF stock.

Range Cancer Therapeutics ETF (CNCR), advised by Exchange Traded Concepts, LLC, is a specialized exchange-traded fund focused on companies engaged in cancer research and treatments. The ETF provides investors with a diversified exposure to the leading companies in oncology, encompassing biopharmaceutical firms, medical device manufacturers, and healthcare service providers actively working on cancer therapies.

On October 23, 2023, CNCR underwent a significant transformation, absorbing the Loncar China BioPharma ETF (CHNA). This reorganization was executed after the close of business on October 20, 2023, allowing shareholders of CHNA to hold shares of CNCR at an equivalent net asset value (NAV). The transition resulted in CNCR issuing approximately 380,835.056 new shares, bringing its total assets to approximately $11,536,010 with an NAV per share of $9.77.

The reorganization was a taxable event, which means shareholders might recognize a gain or loss for federal income tax purposes, except for any gain or loss from the receipt of cash in lieu of fractional shares. Detailed information about this reorganization has been documented in the Information Statement/Prospectus filed with the SEC.

CNCR aims to capture value from the innovative and rapidly evolving field of cancer therapeutics by investing in companies at the forefront of developing breakthrough treatments. The fund is designed to provide a balanced portfolio that mitigates individual company risk while leveraging industry growth potential. As ETFs are traded on exchanges, CNCR shares can be bought and sold throughout the trading day at market prices, which may differ from their NAV.

Investors should consider the investment objectives, risks, charges, and expenses carefully before investing in CNCR. All investing involves risk, and the value of investments may fluctuate. A comprehensive understanding of these factors is essential, and this information is available in the CNCR ETF prospectus accessible via their website or by contacting the fund directly.

Exchange Traded Concepts, LLC, the investment advisor to CNCR, is known for managing thematic and innovative ETFs that provide unique market exposure. The fund is distributed by Quasar Distributors, LLC.

Rhea-AI Summary
Exchange Traded Concepts, LLC announces completion of fund reorganization
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
none

FAQ

What is the current stock price of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR)?

The current stock price of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) is $14.48 as of April 23, 2024.

What is the Range Cancer Therapeutics ETF (CNCR)?

CNCR is an exchange-traded fund that focuses on companies engaged in cancer research and treatments, providing diversified exposure to industry leaders.

What was the recent reorganization involving CNCR?

On October 23, 2023, CNCR absorbed the Loncar China BioPharma ETF (CHNA), resulting in the issuance of approximately 380,835.056 new shares and an increase in total assets to approximately $11,536,010.

How might the reorganization affect shareholders?

The reorganization was a taxable event, meaning shareholders might recognize a gain or loss for federal income tax purposes, except for any cash received in lieu of fractional shares.

What types of companies does CNCR invest in?

CNCR invests in biopharmaceutical firms, medical device manufacturers, and healthcare service providers focused on cancer therapies.

Where can I find detailed information about CNCR?

Detailed information about CNCR can be found in the ETF prospectus available on their website or by calling 1-800-617-0004.

What is the NAV per share of CNCR after the reorganization?

Following the reorganization, CNCR's NAV per share was approximately $9.77.

How does CNCR trade on the stock market?

CNCR shares are traded on exchanges and can be bought and sold throughout the trading day at market prices, which may vary from their NAV.

Who manages CNCR?

CNCR is managed by Exchange Traded Concepts, LLC, with distribution handled by Quasar Distributors, LLC.

What should investors consider before investing in CNCR?

Investors should carefully consider the investment objectives, risks, charges, and expenses detailed in the CNCR ETF prospectus before investing.

How can I contact CNCR for more information?

You can contact CNCR by calling 1-800-617-0004 or visiting their website for more information.
ETF Series Solutions Trust Range Cancer Therapeutics ETF

Nasdaq:CNCR

CNCR Rankings

CNCR Stock Data

1.53M
United States of America